ImpediMed Limited (ASX:IPD) Just Reported, And Analysts Assigned A AU$0.021 Price Target
Analysts Offer Insights on Healthcare Companies: Polynovo (OtherCALZF), Clinuvel Pharmaceuticals (OtherCLVLF) and Impedimed Limited (OtherIPDQF)
ImpediMed lodges 2026 Corporate Governance Statement and Appendix 4G
12:15 ETSOZO® Digital Health Platform Receives FDA Clearance for Sarcopenia Risk Assessment
IPD: Q4 FY26 delivered revenue growth, strong cash position, and expanded reimbursement coverage